Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of nivolumab-based immunotherapy plus photodynamic therapy for esophageal and gastric cancer
jRCT2051220176Phase 2Recruiting
- Sponsor
- Meiji Seika Pharma Co., Ltd.
- Start
- Feb 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab, ipilimumab, talaporfin sodium, capecitabine, oxaliplatin and 1 more in esophageal cancer and gastric cancer (GC) (4 cohorts), sponsored by Meiji Seika Pharma Co., Ltd. Primary endpoint: Response rate for each cohort. Started Feb 2023; status: recruiting.
02
Drugs
03
Conditions
esophageal cancergastric cancer (GC)
Beyond the preview
Go deeper on jRCT2051220176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051220176.